You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

bluebird bio’s beta-thalassaemia gene therapy rejected by NICE

bluebird bio’s beta-thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s National Institute of Health and Care Excellence (NICE) for use on the NHS.